- Home
- CABA vs MAPS Comparison
CABA vs MAPS Comparison
Compare CABA & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- MAPS
- Stock Information
- Founded
- CABA 2017
- MAPS 2008
- Country
- CABA United States
- MAPS United States
- Employees
- CABA N/A
- MAPS N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- MAPS Computer Software: Prepackaged Software
- Sector
- CABA Health Care
- MAPS Technology
- Exchange
- CABA Nasdaq
- MAPS Nasdaq
- Market Cap
- CABA 118.8M
- MAPS 131.9M
- IPO Year
- CABA 2019
- MAPS N/A
- Fundamental
- Price
- CABA $1.22
- MAPS $1.17
- Analyst Decision
- CABA Strong Buy
- MAPS Strong Buy
- Analyst Count
- CABA 8
- MAPS 1
- Target Price
- CABA $21.00
- MAPS $2.61
- AVG Volume (30 Days)
- CABA 652.6K
- MAPS 612.1K
- Earning Date
- CABA 05-19-2025
- MAPS 05-08-2025
- Dividend Yield
- CABA N/A
- MAPS N/A
- EPS Growth
- CABA N/A
- MAPS N/A
- EPS
- CABA N/A
- MAPS 0.08
- Revenue
- CABA N/A
- MAPS $184,514,000.00
- Revenue This Year
- CABA N/A
- MAPS $0.86
- Revenue Next Year
- CABA N/A
- MAPS $12.85
- P/E Ratio
- CABA N/A
- MAPS $14.24
- Revenue Growth
- CABA N/A
- MAPS N/A
- 52 Week Low
- CABA $0.99
- MAPS $0.70
- 52 Week High
- CABA $13.50
- MAPS $1.65
- Technical
- Relative Strength Index (RSI)
- CABA 44.50
- MAPS 50.93
- Support Level
- CABA $1.23
- MAPS $1.11
- Resistance Level
- CABA $1.41
- MAPS $1.31
- Average True Range (ATR)
- CABA 0.11
- MAPS 0.06
- MACD
- CABA 0.02
- MAPS 0.01
- Stochastic Oscillator
- CABA 39.39
- MAPS 51.72
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.